Literature DB >> 34294701

Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis.

Bo Ye1,2, Dandan Fan3, Weiwei Xiong2, Min Li2, Jian Yuan3, Qi Jiang3, Yuting Zhao2,4, Jianxiang Lin2, Jie Liu2, Yilv Lv1, Xiongjun Wang2, Zhigang Li5, Jianzhong Su6,7, Yunbo Qiao8.   

Abstract

The role of cis-elements and their aberrations remains unclear in esophageal squamous cell carcinoma (ESCC, further abbreviated EC). Here we survey 28 H3K27ac-marked active enhancer profiles and 50 transcriptomes in primary EC, metastatic lymph node cancer (LNC), and adjacent normal (Nor) esophageal tissues. Thousands of gained or lost enhancers and hundreds of altered putative super-enhancers are identified in EC and LNC samples respectively relative to Nor, with a large number of common gained or lost enhancers. Moreover, these differential enhancers contribute to the transcriptomic aberrations in ECs and LNCs. We also reveal putative driver onco-transcription factors, depletion of which diminishes cell proliferation and migration. The administration of chemical inhibitors to suppress the predicted targets of gained super-enhances reveals HSP90AA1 and PDE4B as potential therapeutic targets for ESCC. Thus, our epigenomic profiling reveals a compendium of reprogrammed cis-regulatory elements during ESCC carcinogenesis and metastasis for uncovering promising targets for cancer treatment.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34294701     DOI: 10.1038/s41467-021-24813-2

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  69 in total

1.  Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants.

Authors:  Stephen C J Parker; Michael L Stitzel; D Leland Taylor; Jose Miguel Orozco; Michael R Erdos; Jennifer A Akiyama; Kelly Lammerts van Bueren; Peter S Chines; Narisu Narisu; Brian L Black; Axel Visel; Len A Pennacchio; Francis S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

2.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

3.  Esophageal carcinoma.

Authors:  Anil K Rustgi; Hashem B El-Serag
Journal:  N Engl J Med       Date:  2014-12-25       Impact factor: 91.245

4.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

5.  Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.

Authors:  Mingjun Bi; Zhao Zhang; Yi-Zhou Jiang; Pengya Xue; Hu Wang; Zhao Lai; Xiaoyong Fu; Carmine De Angelis; Yue Gong; Zhen Gao; Jianhua Ruan; Victor X Jin; Elisabetta Marangoni; Elodie Montaudon; Christopher K Glass; Wei Li; Tim Hui-Ming Huang; Zhi-Ming Shao; Rachel Schiff; Lizhen Chen; Zhijie Liu
Journal:  Nat Cell Biol       Date:  2020-05-18       Impact factor: 28.824

6.  Global trends in esophageal cancer.

Authors:  Gautam K Malhotra; Ujwal Yanala; Advaitaa Ravipati; Matthew Follet; M Vijayakumar; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2017-03-20       Impact factor: 3.454

7.  Epigenomic enhancer profiling defines a signature of colon cancer.

Authors:  Batool Akhtar-Zaidi; Richard Cowper-Sal-lari; Olivia Corradin; Alina Saiakhova; Cynthia F Bartels; Dheepa Balasubramanian; Lois Myeroff; James Lutterbaugh; Awad Jarrar; Matthew F Kalady; Joseph Willis; Jason H Moore; Paul J Tesar; Thomas Laframboise; Sanford Markowitz; Mathieu Lupien; Peter C Scacheri
Journal:  Science       Date:  2012-04-12       Impact factor: 47.728

8.  Esophageal cancer incidence and mortality in China, 2009.

Authors:  Wanqing Chen; Yutong He; Rongshou Zheng; Siwei Zhang; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

9.  Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements.

Authors:  Masafumi Muratani; Niantao Deng; Wen Fong Ooi; Suling Joyce Lin; Manjie Xing; Chang Xu; Aditi Qamra; Su Ting Tay; Simeen Malik; Jeanie Wu; Ming Hui Lee; Shenli Zhang; Luke Lin Chuen Tan; Huihoon Chua; Wai Keong Wong; Hock Soo Ong; London Lucien Ooi; Pierce Kah-How Chow; Weng Hoong Chan; Khee Chee Soo; Liang Kee Goh; Steve Rozen; Bin Tean Teh; Qiang Yu; Huck Hui Ng; Patrick Tan
Journal:  Nat Commun       Date:  2014-07-10       Impact factor: 14.919

10.  The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection.

Authors:  Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Nasser K Altorki; Ermanno Ancona; S Michael Griffin; Arnulf Hölscher; Toni Lerut; Simon Law; Thomas W Rice; Alberto Ruol; Jan J B van Lanschot; John Wong; Tom R DeMeester
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

View more
  4 in total

1.  CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer.

Authors:  Wei Dai; Junhong Wu; Xiaopeng Peng; Wen Hou; Hao Huang; Qilai Cheng; Zhiping Liu; Walter Luyten; Liliane Schoofs; Jingfeng Zhou; Shenglan Liu
Journal:  Clin Transl Med       Date:  2022-10

2.  BTG2 Serves as a Potential Prognostic Marker and Correlates with Immune Infiltration in Lung Adenocarcinoma.

Authors:  Xiao Zhen Zhang; Mao Jian Chen; Ping Ming Fan; Wei Jiang; Shi Xiong Liang
Journal:  Int J Gen Med       Date:  2022-03-08

3.  Targeting Aberrant Histone Posttranscription Modification Machinery in Esophageal Squamous Cell Carcinoma: Current Findings and Challenges.

Authors:  Gang Ma; Tongyang Gong; Zhihua Liu
Journal:  Research (Wash D C)       Date:  2022-08-17

4.  Drug repositioning for esophageal squamous cell carcinoma.

Authors:  Adam N Bennett; Rui Xuan Huang; Qian He; Nikki P Lee; Wing-Kin Sung; Kei Hang Katie Chan
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.